The latest update is out from Qiagen ( (QGEN) ).
QIAGEN N.V. has announced a series of managerial transactions involving the release and grant of Performance Stock Units (PSUs) to Thierry Bernard, a member of the managing body. The transactions include the release of 105,600 PSUs from a 2020 grant and 103,400 PSUs from a 2022 grant, with a subsequent receipt of 106,903 common shares. Additionally, 143,229 new PSUs were granted, and 6,600 PSUs were canceled. These transactions are part of the company’s share option programs, reflecting its ongoing efforts to align executive incentives with company performance.
More about Qiagen
QIAGEN N.V. operates in the biotechnology industry, focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its products that enable customers to gain valuable insights from the building blocks of life, DNA, RNA, and proteins.
YTD Price Performance: -13.75%
Average Trading Volume: 1,094,687
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.36B
See more insights into QGEN stock on TipRanks’ Stock Analysis page.